Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era

Abstract: Im We describe here a single-center case series of 27 IC COVID-19 inpatients (mostly with haematological disorders) treated with a combined therapy based on tixagevimab/cilgavimab (T/C) plus small-molecule antivirals (AV), between April 1 2022 and November 30 2022.  Keywords: immunocomp...

Full description

Saved in:
Bibliographic Details
Main Authors: Serena Vita, Emanuela Giombini, Patrizia De Marco, Martina Rueca, Cesare Ernesto Maria Gruber, Alessia Beccacece, Laura Scorzolini, Valentina Mazzotta, Carmen Pinnetti, Priscilla Caputi, Daniele Focosi, Enrico Girardi, Andrea Antinori, Fabrizio Maggi, Alessandra D'Abramo, Emanuele Nicastri, Investigation Team Spallanzani COVID-19 case
Format: Article
Language:English
Published: PAGEPress Publications 2024-04-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Online Access:https://www.mjhid.org/mjhid/article/view/5660
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841562758105006080
author Serena Vita
Emanuela Giombini
Patrizia De Marco
Martina Rueca
Cesare Ernesto Maria Gruber
Alessia Beccacece
Laura Scorzolini
Valentina Mazzotta
Carmen Pinnetti
Priscilla Caputi
Daniele Focosi
Enrico Girardi
Andrea Antinori
Fabrizio Maggi
Alessandra D'Abramo
Emanuele Nicastri
Investigation Team Spallanzani COVID-19 case
author_facet Serena Vita
Emanuela Giombini
Patrizia De Marco
Martina Rueca
Cesare Ernesto Maria Gruber
Alessia Beccacece
Laura Scorzolini
Valentina Mazzotta
Carmen Pinnetti
Priscilla Caputi
Daniele Focosi
Enrico Girardi
Andrea Antinori
Fabrizio Maggi
Alessandra D'Abramo
Emanuele Nicastri
Investigation Team Spallanzani COVID-19 case
author_sort Serena Vita
collection DOAJ
description Abstract: Im We describe here a single-center case series of 27 IC COVID-19 inpatients (mostly with haematological disorders) treated with a combined therapy based on tixagevimab/cilgavimab (T/C) plus small-molecule antivirals (AV), between April 1 2022 and November 30 2022.  Keywords: immunocompromised; SARS-CoV-2 infection; monoclonal antibodies; antivirals; persistent infection; viral evolution
format Article
id doaj-art-30738854fff242a78d2283cc996ef5ee
institution Kabale University
issn 2035-3006
language English
publishDate 2024-04-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-30738854fff242a78d2283cc996ef5ee2025-01-03T00:42:39ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-04-0116110.4084/MJHID.2024.043Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron eraSerena Vita0Emanuela Giombini1Patrizia De Marco2Martina Rueca3Cesare Ernesto Maria Gruber4Alessia Beccacece5Laura Scorzolini6Valentina MazzottaCarmen Pinnetti7Priscilla Caputi8Daniele Focosi9Enrico Girardi10Andrea Antinori11Fabrizio Maggi12Alessandra D'Abramo13Emanuele Nicastri14Investigation Team Spallanzani COVID-19 case15National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNorth-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy2National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyOspedale SpallanzaniNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome ItalyNational Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS- Rome Italy Abstract: Im We describe here a single-center case series of 27 IC COVID-19 inpatients (mostly with haematological disorders) treated with a combined therapy based on tixagevimab/cilgavimab (T/C) plus small-molecule antivirals (AV), between April 1 2022 and November 30 2022.  Keywords: immunocompromised; SARS-CoV-2 infection; monoclonal antibodies; antivirals; persistent infection; viral evolution https://www.mjhid.org/mjhid/article/view/5660
spellingShingle Serena Vita
Emanuela Giombini
Patrizia De Marco
Martina Rueca
Cesare Ernesto Maria Gruber
Alessia Beccacece
Laura Scorzolini
Valentina Mazzotta
Carmen Pinnetti
Priscilla Caputi
Daniele Focosi
Enrico Girardi
Andrea Antinori
Fabrizio Maggi
Alessandra D'Abramo
Emanuele Nicastri
Investigation Team Spallanzani COVID-19 case
Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era
Mediterranean Journal of Hematology and Infectious Diseases
title Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era
title_full Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era
title_fullStr Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era
title_full_unstemmed Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era
title_short Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era
title_sort antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era
url https://www.mjhid.org/mjhid/article/view/5660
work_keys_str_mv AT serenavita antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT emanuelagiombini antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT patriziademarco antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT martinarueca antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT cesareernestomariagruber antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT alessiabeccacece antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT laurascorzolini antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT valentinamazzotta antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT carmenpinnetti antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT priscillacaputi antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT danielefocosi antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT enricogirardi antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT andreaantinori antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT fabriziomaggi antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT alessandradabramo antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT emanuelenicastri antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera
AT investigationteamspallanzanicovid19case antiviralsandmonoclonalantibodycombinationtherapyinhaematologicalpatientsintheomicronera